A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

NCT02569801 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
71
Enrollment
INDUSTRY
Sponsor class

Stopped The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns.

Conditions

Interventions

Sponsor

Genentech, Inc.